The application to cancer vaccine of SSF that mimics pulmonary surfactant
Project/Area Number |
24500527
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Biomedical engineering/Biological material science
|
Research Institution | Musashino University (2013-2014) The University of Tokushima (2012) |
Principal Investigator |
MIZUNO Dai 武蔵野大学, 薬学研究所, 講師 (70380061)
|
Co-Investigator(Renkei-kenkyūsha) |
KIDO Hiroshi 徳島大学, 疾患酵素学研究センター, 特任教授 (50144978)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | 肺サーファクタント / 粘膜免疫 / ワクチン / 生体機能材料 / 抗原デリバリー |
Outline of Final Research Achievements |
The cellular immunity inducing effect of SSF, a synthetic adjuvant that mimics pulmonary surfactant, were shown in this study. Nasal inoculation of vaccine and SSF induced IgG2a antibody, IFN-γ secreting T cell, and cytotoxic T cell. SSF is assumed to be a mucosal adjuvant that useful for cancer vaccine therapy.
|
Report
(4 results)
Research Products
(22 results)
-
-
-
-
-
-
[Journal Article] Immunomodulator clarithromycin enhamces mucosal and systemic immune responses and reduces re-infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitor: A retrospective analysis.2013
Author(s)
Wakako Shinahara, Etsuhisa Takahashi, Takako Sawabuchi, Masaru Arai, Nobuo Hirotsu, Yoshio Takasaki, Shizuo Shindo, Kyoko Shibao, Takashi Yokoyama, Kiyoshi Nishikawa, Masahiro Mino, Minako Iwaya, Yuji Yamashita, Satoshi Suzuki, Dai Mizuno, Hiroshi Kido
-
Journal Title
PLoS ONE
Volume: 8(7)
Issue: 7
Pages: e70060-e70060
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-